Cochrane · systematic review · CD015209
Janus kinase inhibitors for the treatment of COVID‐19
Kramer, A, Prinz, C, Fichtner, F, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
7
No studies
1
Included studies
NR
No studies 1 · 12.5%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 12.5%Moderate 5 · 62.5%High 1 · 12.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
JAK inhibitors plus standard of care compared to standard of care (plus/minus placebo) in individuals with moderate to severe COVID‐19
Population: hospitalised people with confirmed SARS‐CoV‐2 infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes(Time frame of absolute effects) JAK inhibitors plus standard of care vs standard of care (plus/minus placebo) | no estimate extracted | NR | No studies |
All‐cause mortality (up to day 28) JAK inhibitors plus standard of care vs standard of care (plus/minus placebo) | no estimate extracted | 6 studies · 11145 participants | Moderate |
All‐cause mortality (up to day 60) JAK inhibitors plus standard of care vs standard of care (plus/minus placebo) | no estimate extracted | 2 studies · 1626 participants | High |
Improvement in clinical status: discharged alive or hospitalised, but no longer requiring ongoing medical care (up to day 28) JAK inhibitors plus standard of care vs standard of care (plus/minus placebo) | no estimate extracted | 4 studies · 10802 participants | Moderate |
Worsening of clinical status: new need for invasive mechanical ventilation or death (at day 28) JAK inhibitors plus standard of care vs standard of care (plus/minus placebo) | no estimate extracted | 2 studies · 9417 participants | Moderate |
Adverse events (any grade) JAK inhibitors plus standard of care vs standard of care (plus/minus placebo) | no estimate extracted | 3 studies · 1885 participants | Moderate |
Serious adverse events JAK inhibitors plus standard of care vs standard of care (plus/minus placebo) | no estimate extracted | 4 studies · 2901 participants | Moderate |
Secondary infection JAK inhibitors plus standard of care vs standard of care (plus/minus placebo) | no estimate extracted | 4 studies · 10041 participants | Low |